Article Text
Abstract
Infectious and parasitic diseases cause massive health problems in the developing world. Research and development of drugs for diseases that mainly affect poor people in developing countries is limited. The advance market commitment (AMC) idea is an incentivising mechanism for research and development of drugs for neglected diseases. Discussion of the AMC idea is of renewed interest given the launch in June 2009 of the first AMC. This pilot AMC is designed to, among other things, test the idea for potential future applications. This paper is a critique of the AMC idea. It seeks to show that the idea has a hitherto unrecognised theoretical flaw that should make policy-makers and donors hesitant to embrace future applications of the idea.
- Business
- philosophical ethics
Statistics from Altmetric.com
Footnotes
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Other content recommended for you
- How should GAVI build on its success?
- Innovative financing to fund surgical systems and expand surgical care in low-income and middle-income countries
- It is not too late to achieve global covid-19 vaccine equity
- Rethinking global access to vaccines
- Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries
- Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis
- A pneumococcal vaccine is launched in Africa to cut child deaths
- Political economy of covid-19: extractive, regressive, competitive
- Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
- Towards a new model of global health justice: the case of COVID-19 vaccines